What Is B12?

Published August 2026 · Patriot Labs Research Team · ~16 min read

What B12 actually is

Start with the naming, because it is genuinely confusing. “Vitamin B12” is a nutritional label. “Cobalamin” is the chemical family. “Corrinoid” is the wider structural class that includes cobalamins along with a set of related cobalt complexes that share the ring system but carry a different lower base — and, as the analytical literature shows, some of those relatives are not biologically equivalent at all. So B12 is not one molecule. It is a small family of closely related cobalt complexes, only two of which do catalytic work in mammals.

Three facts distinguish it from everything else in a vitamin table. It is the largest and most structurally complex of the vitamins, by a wide margin. It is the only one built around a metal ion. And no plant or animal makes it — the complete biosynthetic route is confined to certain bacteria and archaea, which is why the entire global supply of the molecule, dietary or manufactured, traces back to microbial synthesis.

The structure was not obvious. It was solved by X-ray crystallography and published in Nature in 1956 by Hodgkin, Kamper, Mackay, Pickworth, Trueblood and White, in a paper titled simply “Structure of Vitamin B12”. At the time it was among the most complex structures ever determined by the method, and the difficulty was the point: the molecule has no symmetry to exploit and a ring system nobody had seen before.

It is worth saying plainly, since this site is otherwise a peptide catalogue: none of the peptide literature transfers here. B12 has no amino acids, no peptide bonds, no sequence, no secondary structure. If you have read what are peptides, essentially every generalisation in it — proteolytic degradation, sequence-driven receptor binding, solid-phase synthesis — is irrelevant to a corrinoid. B12 sits next to something like NAD+ in the catalogue: a cofactor, not a signalling peptide.

The corrin ring and the cobalt atom

The core of the molecule is the corrin ring, and the most useful way to understand it is by comparison with the porphyrin ring of heme, which most readers already have a mental picture of.

A porphyrin is four pyrrole-type rings joined into a macrocycle by four one-carbon meso bridges. It is highly conjugated, close to planar, and fourfold symmetric. In the middle sits iron, coordinated by the four ring nitrogens, doing redox chemistry and reversible ligand binding — oxygen transport in hemoglobin, electron transfer in the cytochromes.

A corrin is the same idea with one structural amendment that changes everything downstream. One of the four bridging carbons is missing: rings A and D are joined directly, carbon to carbon, contracting the macrocycle. That contraction has three consequences. The ring is smaller, so it grips a metal ion of slightly different size preference. It is less conjugated and considerably more reduced than a porphyrin, which makes it non-planar and flexible rather than a rigid plate. And it is asymmetric, which means the two faces of the ring are chemically distinguishable — the basis of everything in the next section.

The metal at the centre is cobalt rather than iron, and this is the only place in well-characterised mammalian biochemistry where cobalt appears as a functional metal. Cobalt is not merely an iron substitute. It accesses three oxidation states that matter here — Co(III), Co(II) and Co(I) — and the reduced Co(I) state is an unusually powerful nucleophile, often described in the mechanistic literature as a supernucleophile. That reactivity is what allows cobalamin to make and break bonds to carbon.

Around the ring sit acetamide and propionamide side chains, and one of those propionamide arms is extended: it runs down into an aminopropanol linker, a phosphate, a ribose, and finally a 5,6-dimethylbenzimidazole base. That tail loops back underneath the ring so the benzimidazole nitrogen coordinates the cobalt from below. Bito and colleagues, writing in Molecules in 2020, put it compactly — cobalamin “has a cobalt-coordinated nucleotide, which provides its base (5,6-dimethylbenzimidazole) as the lower axial ligand”. This is the “base-on” configuration; in some enzyme active sites the benzimidazole is displaced by a protein histidine instead, a “base-off, His-on” arrangement.

That accounts for five of the cobalt's six coordination positions: four equatorial nitrogens from the corrin, one lower axial nitrogen from the tail. The sixth — the upper, or beta-axial, position — is left open. Everything that distinguishes one cobalamin from another happens there.

One incidental property is worth flagging because it matters at the bench: the corrin chromophore is intensely coloured. Cobalamin solutions are deep red to pink, which is both a convenient identity cue and a useful stability indicator, since degradation chemistry tends to change the visible spectrum.

The four forms and the beta-axial position

The four cobalamins routinely discussed differ only in what occupies that one open coordination site. Everything else — ring, side chains, nucleotide tail, cobalt — is identical.

The two alkylcobalamins — methyl and adenosyl — are the biologically active coenzyme forms. They are the ones with a genuine cobalt–carbon bond, and that bond is the chemistry the enzymes exploit. The cyano and hydroxo forms have no catalytic role of their own.

What happens to the non-coenzyme forms inside a cell is a distinct processing pathway rather than a passive equilibrium. Evidence for a dedicated processing step goes back to Mellman, Willard, Youngdahl-Turner and Rosenberg, who reported in the Journal of Biological Chemistry in 1979 on cobalamin coenzyme synthesis in normal and mutant human fibroblasts and described a processing enzyme activity deficient in cblC cells. The protein responsible is now known as MMACHC, or CblC, and it is the subject of a dedicated chapter in the 2022 Vitamins and Hormones volume on vitamin B12. In outline: the upper ligand is stripped — decyanation for the cyano form, dealkylation for alkylcobalamins — leaving a cob(II)alamin intermediate, which is then routed either to the mitochondrion for adenosylation, producing adenosylcobalamin for the mutase, or retained in the cytosol where methionine synthase itself acquires a methyl group from the folate pool. Gherasim, Lofgren and Banerjee summarised this territory in 2013 under the title “Navigating the B12 Road: Assimilation, Delivery, and Disorders of Cobalamin”, which is a fair description of how many hand-offs are involved.

Two honest observations about the marketing that surrounds these forms. First, the claim that a coenzyme form is inherently superior to a cyano or hydroxo form is contested rather than settled — Obeid, Fedosov and Nexo published a 2015 review in Molecular Nutrition & Food Research whose title states the position directly: “Cobalamin coenzyme forms are not likely to be superior to cyano- and hydroxyl-cobalamin in prevention or treatment of cobalamin deficiency”. We cite that here to show the question is genuinely argued in the literature, not to give anyone guidance about anything.

Second, and more relevant at the bench: structural similarity is not functional equivalence. Bito and colleagues tested pseudovitamin B12 — adenyl cobamide, a corrinoid carrying adenine instead of dimethylbenzimidazole as the lower base — in cultured COS-7 cells and reported that the hydroxo form functioned as a coenzyme for methionine synthase but with markedly lower affinity than hydroxocobalamin, while the adenosyl form “did not function as a coenzyme or an inhibitor of methylmalonyl-CoA mutase”. A near-identical ring system with the wrong lower base is not B12 in any functional sense. That is a strong argument for treating corrinoid identity as an analytical question rather than assuming it.

Why cyanocobalamin is the manufactured standard

Cyanocobalamin is the form most manufactured material takes, and the reason is stability rather than biology.

Cyanide is a strong-field ligand and forms a robust bond to Co(III). Compare that with the alternatives. The cobalt–carbon bonds of methylcobalamin and adenosylcobalamin are, by design, weak enough to break under enzymatic control — adenosylcobalamin's Co–C bond exists precisely because it can be homolysed to generate a radical. A bond built to break easily in an active site also breaks easily in a vial exposed to light. Hydroxocobalamin sits between the two: more stable than the alkyl forms, more reactive than the cyano form, and readily exchanges its upper ligand.

Cyanocobalamin, by contrast, crystallises cleanly, tolerates handling, and holds up in storage far better than either coenzyme form. That combination — a defined, crystalline, comparatively photostable solid produced at scale by bacterial fermentation and then converted to the cyano form — is why it became the reference article of commerce. It is standardised enough that a compendial monograph exists for cyanocobalamin injection in the United States Pharmacopeia–National Formulary, which is a useful marker of how well characterised the material is analytically.

The honest framing is this: cyanocobalamin's stability is a property of the manufacturing chain, not evidence of biological superiority. It is essentially inert until a cell processes it. Whether that processing step matters is exactly the question the Obeid review addresses, and it is not a question this guide takes a position on.

The two mammalian B12-dependent enzymes

Bacteria use cobalamin in a long list of reactions. Mammals use it in two, and that is not a simplification — it is the empirical finding. Kolhouse and Allen reported in the Proceedings of the National Academy of Sciences in 1977 on the recognition of two intracellular cobalamin binding proteins and their identification as methylmalonyl-CoA mutase and methionine synthetase. Nearly fifty years later the list is still two, and a 2022 chapter in Methods in Enzymology is titled, flatly, “Human B12-dependent enzymes: Methionine synthase and Methylmalonyl-CoA mutase”. Banerjee and Ragsdale's 2003 Annual Review of Biochemistry article, “The Many Faces of Vitamin B12: Catalysis by Cobalamin-Dependent Enzymes”, is the standard mechanistic survey of the underlying chemistry.

Methionine synthase catalyses a methyl transfer. The methyl group is taken from 5-methyltetrahydrofolate onto the cobalt, generating methylcobalamin, and then handed on to the sulfur of homocysteine to give methionine. The mechanism cycles the cobalt between Co(I) and Co(III), and the Co(I) intermediate is the supernucleophile mentioned earlier. Methionine is in turn the precursor of S-adenosylmethionine, the general-purpose methyl donor for methylation of DNA, RNA, histones, phospholipids and small molecules. This is the sense in which B12 is a “methylation” cofactor: it sits at one specific node of a pathway, not as a general enhancer of anything.

The Co(I) intermediate is chemically fragile. Occasional oxidation to Co(II) leaves the enzyme catalytically dead, and it has to be rescued by reductive remethylation, a repair reaction requiring methionine synthase reductase and S-adenosylmethionine. This is one of the few enzymes in mammalian metabolism with a dedicated repair partner, which tells you something about how demanding its chemistry is.

A widely used experimental handle on this enzyme is nitrous oxide, which oxidises the cobalt and inactivates methionine synthase. Riedel, Fiskerstrand, Refsum and Ueland used this in human glioma cells and reported co-ordinate variations in methylmalonyl-CoA mutase and methionine synthase, and in the cobalamin cofactors, during nitrous oxide exposure and the subsequent recovery phase — a cell-culture model that lets the two arms of B12 biochemistry be perturbed and watched separately.

Methylmalonyl-CoA mutase does something chemically stranger. It catalyses a carbon-skeleton rearrangement: a thioester group migrates along the backbone, converting L-methylmalonyl-CoA into succinyl-CoA. Rearrangements of this kind are difficult, and the enzyme solves the problem with radicals. The cobalt–carbon bond of adenosylcobalamin undergoes homolysis, producing cob(II)alamin and a 5′-deoxyadenosyl radical. That radical abstracts a hydrogen atom from the substrate, the resulting substrate radical rearranges, and the hydrogen is returned. Adenosylcobalamin here is best understood as a controlled radical generator — the enzyme's job is to make a very reactive species and keep it on a leash.

The leash occasionally slips. Vlasie and Banerjee published a 2004 Biochemistry paper with the memorable title “When a Spectator Turns Killer: Suicidal Electron Transfer from Cobalamin in Methylmalonyl-CoA Mutase”, which is a fair summary of the failure mode: cofactor side-reactions can inactivate the enzyme, and there is dedicated machinery for cofactor rescue and replacement.

Functionally, this reaction is the exit route for propionyl-CoA-derived carbon. Propionyl-CoA arrives from the catabolism of odd-chain fatty acids, several amino acids and cholesterol side chains, is carboxylated to methylmalonyl-CoA, and can only reach the TCA cycle through the mutase. Block the mutase and that carbon has nowhere to go.

Methionine synthase, folate and the methyl trap

This is the most elegant piece of logic in B12 biochemistry, and it explains an observation that would otherwise look like coincidence.

Folate circulates through a cycle of one-carbon carriers at different oxidation levels, feeding thymidylate synthesis, purine synthesis and methylation. One step in that cycle — the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate by methylenetetrahydrofolate reductase — is effectively irreversible under cellular conditions. Folate that goes down that road is committed.

And there is exactly one way back out in mammals: methionine synthase, which strips the methyl group off 5-methyltetrahydrofolate and hands it to homocysteine, regenerating tetrahydrofolate. That single reaction is the only exit from the 5-methyl pool.

So if methionine synthase is impaired — through absent cofactor, oxidised cobalt, or a genetic lesion — folate progressively accumulates in the 5-methyl form and becomes functionally unavailable for the reactions that need other one-carbon species. The cell can be replete with total folate and starved of usable folate at the same time. This is the methyl-folate trap hypothesis, and it is why impaired B12 biochemistry and impaired folate biochemistry converge on the same downstream picture, particularly in rapidly dividing cells that depend on thymidylate synthesis. Sauer and Wilmanns set out the argument in the British Journal of Haematology in 1977 under the title “Cobalamin Dependent Methionine Synthesis and Methyl-Folate-Trap in Human Vitamin B12 Deficiency”.

It is worth keeping the word “hypothesis” attached. The model is long-standing, mechanistically coherent and widely taught, and the enzymology it rests on is not in doubt. It is still a model of how a deficiency state unfolds, and the quantitative details — how fast the trap develops, how completely, and how much it explains in any given tissue — are not something a guide like this should pretend are settled.

Homocysteine and methylmalonic acid as biochemical readouts

The two-enzyme architecture produces a neat analytical consequence. Each enzyme, when impaired, backs up a different metabolite.

Methionine synthase impairment leaves homocysteine unconverted, so total homocysteine rises. Methylmalonyl-CoA mutase impairment leaves L-methylmalonyl-CoA unrearranged; it accumulates and is hydrolysed to free methylmalonic acid, which rises in turn. Because homocysteine is also affected by folate status and by other parts of sulfur amino acid metabolism, while methylmalonic acid is much more specific to the mutase reaction, the two behave differently as indicators.

This pairing has been studied for decades. Allen, Stabler, Savage and Lindenbaum published companion papers in the American Journal of Hematology in 1990: the first on the usefulness of serum methylmalonic acid and total homocysteine concentrations in diagnosing cobalamin deficiency, the second on the relative sensitivities of serum cobalamin, methylmalonic acid and total homocysteine concentrations. Obeid and Herrmann later compared holotranscobalamin against total cobalamin and methylmalonic acid in Clinical Chemistry and Laboratory Medicine in 2007.

Two things need saying about that literature. It is clinical in origin, and this guide is not repeating it as guidance of any kind — it is cited here because it establishes the biochemical point that the two enzyme arms produce distinguishable metabolite signatures. And the picture is not uniformly clean: Shojania published a 2005 letter in Blood titled “Cobalamin-responsive disorders and unreliability of cobalamin, methylmalonic acid, and homocysteine testing”, which is a reminder that even the best-established B12 markers have contested performance. Nothing here should be read as a basis for interpreting anyone's results.

Absorption: the most elaborate pathway in vitamin biology

Most vitamins are absorbed by a transporter or by passive diffusion. B12 is handled by a relay of three distinct binding proteins and a dedicated receptor complex, and the title of the standard review says it best — Nielsen, Rasmussen, Andersen, Nexø and Moestrup published “Vitamin B12 transport from food to the body's cells — a sophisticated, multistep pathway” in Nature Reviews Gastroenterology & Hepatology in 2012.

The sequence, in outline:

Release. Dietary cobalamin arrives bound to protein and has to be liberated by gastric acid and pepsin before anything else can happen.

Haptocorrin. The freed cobalamin is picked up not by intrinsic factor but by haptocorrin, historically called R-binder. Haptocorrin binds cobalamin tightly at acidic pH and, importantly, is promiscuous — it binds a range of corrinoid analogues that are not functional B12. It behaves like a scavenger and a chaperone through the acidic stomach.

Hand-off. In the duodenum, pancreatic proteases degrade haptocorrin at neutral pH, releasing its cargo. Only now does intrinsic factor, a glycoprotein secreted by gastric parietal cells, take over — and intrinsic factor is far more selective than haptocorrin about what it will carry.

The cubam receptor. The intrinsic-factor–cobalamin complex travels to the distal ileum, where it is bound by a receptor that took a long time to characterise. Fyfe, Madsen, Højrup, Christensen, Tanner, de la Chapelle, He and Moestrup reported in Blood in 2004 that “the functional cobalamin (vitamin B12)–intrinsic factor receptor is a novel complex of cubilin and amnionless” — two separate proteins acting as one unit, since named cubam. He and colleagues reported in the same journal in 2005 that amnionless function is required for cubilin brush-border expression and intrinsic factor–cobalamin absorption in vivo. Pedersen, Chakraborty, Steinhauser, Traub and Madsen described in Traffic in 2010 how the amnionless subunit directs endocytosis of cubam by engaging the adaptors ARH or Dab2. The receptor's wider biology is reviewed by Kozyraki and Cases in Current Medicinal Chemistry in 2020 and in a chapter of the 2022 Vitamins and Hormones volume.

Intracellular processing. Inside the enterocyte, intrinsic factor is degraded and cobalamin is exported from the lysosome, entering the cytosol where the MMACHC processing step described earlier removes the upper axial ligand.

Transcobalamin II. Cobalamin leaves the enterocyte bound to transcobalamin II. This is the fraction — holotranscobalamin — that peripheral cells can actually take up through a specific receptor. The majority of cobalamin circulating in plasma is bound to haptocorrin instead, and that pool is not readily delivered to cells. This is a large part of why total serum cobalamin is an imperfect indicator, and why holotranscobalamin was investigated as an alternative.

Step back and the design is remarkable: a scavenging binder for the acidic compartment, a selective binder for the intestine, a two-protein receptor with its own endocytic adaptors, an intracellular ligand-stripping enzyme, and a third binder for delivery. Every stage is a potential point of failure, and every stage adds a variable to any attempt to reason about B12 status from a single measurement. The complexity is not decoration — it is the reason this vitamin's biology is harder than it looks.

The cyanide question, honestly

“Cyanocobalamin contains cyanide” is technically true and almost always deployed misleadingly, so it is worth doing the arithmetic.

The cyanide in cyanocobalamin is a single monodentate ligand coordinated to cobalt — one cyanide ion per molecule, held in a coordination bond rather than floating free. Cyanocobalamin has a molecular mass in excess of 1,300 daltons; a cyanide ion is 26. The cyanide is therefore on the order of two per cent of the molecule's mass, and it is not present as free cyanide at all while it is bound to the metal.

There is exactly one context in which cobalamin–cyanide chemistry is discussed as consequential, and it runs in the opposite direction. Hydroxocobalamin is used as a cyanide-binding agent: it exchanges its hydroxide ligand for cyanide, forming cyanocobalamin, which sequesters the cyanide. That reaction has been characterised analytically — Houeto, Levillain, Hoffman, Baud and Imbert reported in The Lancet in 1995 on the relation of blood cyanide to plasma cyanocobalamin concentration after a fixed dose of hydroxocobalamin in cyanide poisoning, and Astier and Baud published a chromatographic method for the simultaneous determination of hydroxocobalamin and its cyanide complex cyanocobalamin in human plasma in the same year. Houeto and colleagues had earlier described a derivative spectrophotometric method for distinguishing the two forms in that setting.

Note carefully what those papers establish: that cobalamin can act as a cyanide scavenger, and that the resulting cyanocobalamin can be measured. They are about a molecule mopping cyanide up. Reading them backwards — as though the cyanide ligand in ordinary cyanocobalamin were a hazard of the same character — inverts both the direction of the chemistry and the quantities involved, which differ by orders of magnitude. It is the same reason nobody worries about the chloride in sodium chloride.

The genuinely interesting point for a laboratory is not toxicological but analytical: because the upper ligand exchanges, cyanide contamination in a buffer or reagent stream can convert other cobalamin forms to cyanocobalamin during sample handling, which is a real source of artefact when the question is which form was present in the first place.

Photosensitivity, amber glass and analytics

Cobalamins are photosensitive, and the reason is structural. The cobalt–carbon bonds of methylcobalamin and adenosylcobalamin are exactly the sort of bond that undergoes photolytic homolysis — the same reactivity the mutase harnesses deliberately is available to a photon. Cyanocobalamin is substantially more robust, but cobalamins as a class degrade under light: Juzeniene and Nizauskaite published on the photodegradation of cobalamins in aqueous solutions and in human blood in the Journal of Photochemistry and Photobiology B in 2013.

This is why cobalamin material is conventionally supplied and handled in amber glass, or in clear glass kept boxed or foil-wrapped, and why light exposure is minimised during weighing, dissolution and analysis. It is not a marketing flourish; it is the standard precaution for a photolabile chromophore. The intense red colour is a rough qualitative cue — noticeable fading or a shift in hue is a reason to characterise the material rather than assume it.

General stability considerations follow the same logic as any small-molecule reference material: cool, dark, dry, tightly closed, protected from light and from repeated temperature excursions, with solution stability characterised rather than assumed for anything beyond short experimental windows. The storage guide and the degradation guide cover the general framework, with the caveat that the specific chemistry there is peptide chemistry — hydrolysis, oxidation, deamidation — and a corrinoid's failure modes are ligand exchange, photolysis and cobalt redox chemistry instead.

On the analytical side, B12 is unusually well served. The visible absorption spectrum differs between forms, which supports spectrophotometric discrimination — the derivative spectrophotometry work cited above rests on exactly that. HPLC separates the forms, and liquid chromatography–tandem mass spectrometry methods have been published for cobalamins in plasma, including the work of Schwertner, Valtier and Bebarta in the Journal of Chromatography B in 2012. A compendial monograph for cyanocobalamin injection exists in USP–NF, which means identity, assay and impurity expectations for the material are formally specified somewhere public.

Practically, that means documentation for a corrinoid should be read differently from documentation for a peptide. The COA guide covers how to read a certificate generally; for B12 the questions worth asking are which form the material is, how identity was confirmed spectroscopically or by mass, and whether the assay distinguishes cobalamin from related corrinoids — because, as the pseudovitamin work above demonstrates, a corrinoid with the wrong lower base can be inert at one of the two enzymes while still looking broadly B12-like.

What the evidence does not establish

This is the section that matters most on this particular page, because B12 is the compound most likely to attract claims it cannot support.

Established enzymology is not an outcome claim. That methionine synthase requires methylcobalamin and that methylmalonyl-CoA mutase requires adenosylcobalamin is textbook, well replicated and not in dispute. That says nothing whatsoever about what supplied material does in any organism. A pathway description is not a result.

The catalogue language is pathway language. B12 is described in the product listing as studied for energy metabolism, methylation and nervous-system support. Those phrases point at the biochemistry above — propionyl-CoA carbon entering the TCA cycle, the methionine/SAM methyl pool, and the fact that impaired B12 biochemistry has neurological correlates in the deficiency literature. They are not, and must not be read as, statements that any product produces an effect in a person. This guide makes no such statement anywhere.

Deficiency biology is not treatment guidance. Elevated total homocysteine and elevated methylmalonic acid are metabolite consequences of impaired enzyme function, described here as enzymology. They are not diagnostic criteria as presented here, they are not a reason to purchase anything, and their performance as indicators is itself contested in the literature.

Form superiority is unsettled. The frequent claim that methylcobalamin or adenosylcobalamin is inherently better than cyanocobalamin is an argument, not a finding — and the 2015 review by Obeid, Fedosov and Nexo argues the opposite conclusion in its title. A guide that presented either side as settled would be overstating the literature.

Cell-culture models carry the usual caveats. The mechanistic work cited here uses immortalised lines — COS-7 cells, human glioma cells — along with fibroblast systems and purified enzymes. These are appropriate models for asking whether a cofactor supports catalysis. They are not models of an intact organism, and results in them do not transfer to one without a great deal of additional work.

Most of the pathway detail rests on reviews cited bibliographically. For several sources in the reference list below, the bibliographic record was verified but full text was not retrieved in preparing this guide. Those are marked. Where a claim rests only on a title, this guide states no more than the title supports.

Nothing here concerns human use. The material stocked here is for laboratory research. It is not an approved product for consumption, this guide does not describe how to use it, and no amount, concentration or procedure appears anywhere on this page by design.

Frequently asked questions

What is B12, chemically? A corrinoid: a cobalt ion held by four nitrogens of a contracted tetrapyrrole macrocycle called corrin, with a dimethylbenzimidazole nucleotide looping back to coordinate the cobalt from below and one variable ligand position above. It is the only vitamin containing a metal ion, and cobalamin is the only well-characterised cobalt-containing molecule in biology. The structure was published by Hodgkin and colleagues in Nature in 1956.

How is corrin different from the porphyrin in heme? One of porphyrin's four one-carbon bridges is absent in corrin, so rings A and D join directly. The result is a smaller, more reduced, non-planar and asymmetric macrocycle holding cobalt rather than iron. The asymmetry is what makes the two faces of the ring chemically distinct, and the cobalt is what allows organometallic chemistry that iron-porphyrin systems do not perform.

Which forms are the active coenzymes? Methylcobalamin and adenosylcobalamin — the two with a genuine cobalt–carbon bond. Methylcobalamin serves cytosolic methionine synthase; adenosylcobalamin serves mitochondrial methylmalonyl-CoA mutase. Cyanocobalamin and hydroxocobalamin are not coenzymes; their upper ligand is removed by the MMACHC processing enzyme before the coenzyme forms are assembled.

Is cyanocobalamin natural? Not meaningfully. It is generally described as an artefact of the classical isolation chemistry rather than a compound of biological origin. It is the standard manufactured form because it is by some margin the most stable — the cobalt–cyanide bond resists the photolysis and homolysis that the alkylcobalamins undergo readily. Stability is a manufacturing property, not a biological credential.

Should the cyanide in cyanocobalamin be a concern? Stoichiometrically it is one coordinated cyanide ion on a molecule of more than 1,300 daltons — on the order of two per cent by mass, and bound to cobalt rather than free. The one context where cobalamin–cyanide chemistry is treated as significant runs the other way: hydroxocobalamin acts as a cyanide-binding agent, exchanging hydroxide for cyanide to form cyanocobalamin, as characterised in The Lancet in 1995 and in the associated analytical methods literature.

Why is B12 handled in amber vials? Because cobalamins are photosensitive. The cobalt–carbon bonds of the coenzyme forms are precisely the sort that undergo photolytic homolysis, and cobalamins as a class degrade under light — the subject of Juzeniene and Nizauskaite's 2013 paper on photodegradation of cobalamins in aqueous solutions and in human blood. Amber glass, foil wrapping and reduced light exposure during handling are the standard precautions for a photolabile chromophore.

Is B12 approved for human use? No. The material stocked here is sold strictly for in-vitro research and laboratory use only, and is not intended for human or veterinary consumption. This guide describes chemistry, enzymology and published literature; it is not medical advice, it does not describe how to use any product, and none of the references cited constitute a product claim.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes peptide chemistry and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.